The HLA-B27 test is a blood test that checks whether you carry a specific protein marker on the surface of your white blood cells, one that is strongly linked to a group of inflammatory conditions affecting the spine, joints, and eyes. It is most commonly ordered when a doctor suspects ankylosing spondylitis or another spondyloarthropathy, but the result is never a simple yes-or-no diagnosis. Carrying the marker raises your risk substantially, yet most people who test positive never develop any related disease, and some people who test negative still do.
What HLA-B27 Actually Is
HLA stands for human leukocyte antigen, a family of proteins your immune system uses to distinguish your own cells from foreign invaders. Think of HLA molecules as tiny display shelves on the surface of your cells: they grab fragments of proteins from inside the cell and hold them up so immune cells can inspect them. If the fragment looks foreign, the immune system attacks. HLA-B27 is one specific version of the HLA-B gene, and it shapes the display shelf in a way that, for reasons researchers are still working out, sometimes triggers the immune system to attack the body’s own tissues.
Research points to the antigen-presentation process itself as the key event in disease. Comparing two very similar subtypes of HLA-B27 that differ by a single amino acid, scientists found that one is associated with ankylosing spondylitis and the other is not, suggesting that the exact shape of the molecule’s groove determines whether it provokes an autoimmune response.1Elsevier / PubMed Central. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity In other words, HLA-B27 is not inherently dangerous. It is one variant of a normal immune molecule, and only certain subtypes, in certain people, under certain circumstances, lead to trouble.
Why Doctors Order the Test
The HLA-B27 test is not a routine screening test. You will not find it on a standard blood panel. Doctors order it when they already suspect something specific based on your symptoms and exam, and the result helps them decide how likely a particular diagnosis is.
The most common reason is chronic inflammatory back pain in a younger adult. If you are under 45 and have had persistent low back pain for more than three months that improves with movement but gets worse with rest, your doctor may suspect axial spondyloarthritis, the umbrella term that includes ankylosing spondylitis. A positive HLA-B27 result in that context makes the diagnosis considerably more likely. A negative result does not rule it out, but it shifts the probability.
The test is also ordered when someone develops acute anterior uveitis, a painful inflammation of the front of the eye. Symptoms include sensitivity to light, eye redness, pain, and blurred vision. Uveitis can be the first visible sign of an underlying spondyloarthropathy, so ophthalmologists and rheumatologists look for HLA-B27 as part of the workup. A thorough history checking for inflammatory back pain, peripheral joint swelling, gastrointestinal or urinary tract problems, and skin changes can help catch a spondyloarthropathy early when someone presents with eye inflammation.2PubMed Central. Review for Disease of the Year: Epidemiology of HLA-B27 Associated Ocular Disorders
Other scenarios where the test comes up include reactive arthritis, which typically follows a gut or urinary tract infection; psoriatic arthritis with spinal involvement; and inflammatory bowel disease when joint symptoms are also present. In each case, the test adds a piece to the puzzle rather than solving it outright.
What a Positive Result Means
A positive HLA-B27 result tells you that your white blood cells carry this particular protein. It does not tell you that you have, or will develop, any disease. A positive status indicates an increased genetic predisposition to certain autoimmune diseases, notably ankylosing spondylitis, reactive arthritis, and other spondyloarthropathies, but it is not diagnostic on its own.3Multidisciplinary Digital Publishing Institute (MDPI). HLA-B27 Status in Rheumatic Diseases: Clinical and Immunological Differences Between Positive and Negative Patients—A Comparative Study
This distinction is worth sitting with because it is the most common source of unnecessary anxiety. Somewhere around 6 to 8 percent of the general population in many Western countries carries HLA-B27. Of those people, only a small fraction, estimates vary but are often cited in the range of 5 to 20 percent, will ever develop ankylosing spondylitis or a related condition. So if you test positive and feel fine, the odds are firmly in your favor.
Where a positive result carries real weight is when it lands alongside suggestive symptoms, imaging findings, or lab markers of inflammation. Ankylosing spondylitis is widely regarded as an inherited disease, with over 90 percent of the risk of developing it attributed to HLA-B27.4PubMed Central. Ankylosing spondylitis risk factors: a systematic literature review That is an enormous genetic contribution compared to most autoimmune conditions. But “90 percent of the risk” refers to the genetic architecture of the disease, not to any individual’s chances. Your doctor is looking at the full clinical picture, not just one lab value.
What a Negative Result Means
A negative result means your blood cells do not display HLA-B27, and for many people, that provides meaningful reassurance. But it does not slam the door shut on a diagnosis of spondyloarthritis.
Research into HLA-B27-negative axial spondyloarthritis makes this clear. The negative predictive value of the test, meaning how well a negative result rules out the disease, ranges from roughly 55 to 81 percent depending on how common HLA-B27 is in the local population.5PubMed Central. Human Leukocyte Antigen B27‐Negative Axial Spondyloarthritis: What Do We Know? That means in populations where HLA-B27 is relatively rare, a negative result is more informative. In populations where the marker is more common, a negative result still leaves a meaningful chance that the disease is present.
People with HLA-B27-negative spondyloarthritis do exist, and they tend to be harder to diagnose. Their disease can look slightly different: they may have less dramatic changes on imaging early on, or their symptoms may overlap more with other causes of back pain. If your doctor strongly suspects spondyloarthritis based on your symptoms and exam but your HLA-B27 comes back negative, the workup does not end there. MRI of the sacroiliac joints, blood markers of inflammation, and clinical criteria all factor in.
How the Test Is Done
The HLA-B27 test is a simple blood draw, no fasting required. The lab uses a technique called flow cytometry or a molecular method like PCR to detect the marker. Results typically come back within a few days to a week, depending on the lab. You do not need to do anything special to prepare, and there are no meaningful risks beyond the minor discomfort of a needle stick.
One thing to know: the result is binary. You either carry HLA-B27 or you do not. There is no “borderline” or “weak positive.” The marker is determined by your genes, so it will not change over time. You only need to be tested once in your life. If you tested positive five years ago, you are still positive, and repeating the test adds nothing.
HLA-B27 and Eye Inflammation
Acute anterior uveitis is the most common extra-articular manifestation linked to HLA-B27, and it is worth knowing about because it can be the first clue that something systemic is going on. The condition strikes suddenly, usually in one eye at a time, and causes redness, pain, light sensitivity, and blurred vision.2PubMed Central. Review for Disease of the Year: Epidemiology of HLA-B27 Associated Ocular Disorders Episodes tend to recur, and many people experience flares in alternating eyes over months or years.
If you have had a bout of uveitis and your ophthalmologist orders HLA-B27 testing, a positive result does two things. First, it helps explain the uveitis itself, since HLA-B27-associated uveitis is a recognized clinical entity with its own treatment approach. Second, it prompts a broader evaluation for spondyloarthropathy. Many patients with HLA-B27-positive uveitis turn out to have subtle spinal or sacroiliac joint inflammation they had not noticed, or had written off as ordinary back stiffness. Catching it early can change the treatment plan and long-term outlook.
Who Carries HLA-B27
The frequency of HLA-B27 varies dramatically around the world. It follows a rough north-to-south gradient, with higher prevalence in northern populations and lower prevalence closer to the equator.6Elsevier. The interplay between the geographic distribution of HLA-B27 alleles and their role in infectious and autoimmune diseases: A unifying hypothesis Among certain Indigenous populations in northern regions, prevalence can exceed 25 percent. In many East Asian populations, it is closer to 2 to 6 percent. In sub-Saharan African populations, it is rarer still.
This geographic variation matters clinically because the predictive value of the test depends on the background rate of HLA-B27 in a given population. In a population where 25 percent of people carry the marker, a positive result is less specific, since many healthy people also test positive. In a population where only 2 percent carry it, a positive result carries more diagnostic weight. Doctors who practice in diverse communities need to factor in the patient’s ethnic background when interpreting results, though this context is not always explicitly communicated to the patient.
The geographic pattern has also led researchers to hypothesize that HLA-B27 may have conferred a survival advantage in certain environments, possibly through better immune defense against specific infections. This would explain why the gene persists at high frequencies despite its association with autoimmune disease. The trade-off between infection resistance and autoimmune risk is a recurring theme in immunology.
Conditions Linked to HLA-B27
The list of conditions associated with HLA-B27 is broader than many people realize. The main ones include:
- Ankylosing spondylitis: Chronic inflammatory disease of the spine and sacroiliac joints. The strongest HLA-B27 association of any condition.
- Reactive arthritis: Joint inflammation that develops after a bacterial infection, often of the gut or urinary tract. HLA-B27 is found in a large proportion of cases.
- Acute anterior uveitis: Painful eye inflammation that can occur on its own or alongside spinal disease.
- Psoriatic arthritis: Joint disease occurring alongside the skin condition psoriasis, particularly when the spine is involved.
- Enteropathic arthritis: Joint inflammation linked to inflammatory bowel diseases like Crohn’s disease and ulcerative colitis.
These conditions are grouped under the umbrella of spondyloarthropathies because they share overlapping features: spinal involvement, enthesitis (inflammation where tendons attach to bone), and an association with HLA-B27. But the strength of the HLA-B27 association varies. It is strongest for ankylosing spondylitis, where over 90 percent of patients in many studies carry the marker, and weaker for psoriatic arthritis, where many patients are HLA-B27-negative.4PubMed Central. Ankylosing spondylitis risk factors: a systematic literature review
Common Misconceptions About HLA-B27 Testing
The biggest misconception is that a positive test equals a diagnosis. It does not. Doctors sometimes struggle to convey this to patients, and patients who see “positive” on a lab report can spiral into anxiety about a condition they may never develop. The test is a risk marker, not a disease marker. It changes the probability of a diagnosis, not the certainty.
A related misconception runs in the other direction: that a negative test means you are in the clear. As discussed, HLA-B27-negative spondyloarthritis is a real and recognized entity. If your symptoms fit, your doctor should continue the workup regardless of the test result.5PubMed Central. Human Leukocyte Antigen B27‐Negative Axial Spondyloarthritis: What Do We Know?
Another common misunderstanding is that HLA-B27 testing can predict how severe your disease will be if you do develop a spondyloarthropathy. The evidence here is mixed. Some studies have found clinical differences between HLA-B27-positive and HLA-B27-negative patients, with positive patients sometimes showing earlier onset or more axial involvement.3Multidisciplinary Digital Publishing Institute (MDPI). HLA-B27 Status in Rheumatic Diseases: Clinical and Immunological Differences Between Positive and Negative Patients—A Comparative Study But these are group-level trends, not reliable predictions for any one person. Your HLA-B27 status alone cannot tell your doctor whether you will have mild or severe disease.
Should You Get Tested if You Feel Fine?
Screening healthy people for HLA-B27 is not recommended by any major medical organization. The reason comes back to the math: most carriers never develop disease, so a positive result in a healthy person creates worry without actionable information. There is no preventive treatment you would start based on a positive result in the absence of symptoms.
The one scenario where proactive testing sometimes comes up is family history. If a first-degree relative has ankylosing spondylitis, you might wonder whether you carry the marker. Knowing your status can be useful in one narrow sense: if you later develop persistent back pain or unexplained eye inflammation, the information could speed up diagnosis. But many rheumatologists would still prefer to test at the point symptoms appear rather than years in advance, because the result without symptoms changes nothing about your care.
If you have already been tested as part of a routine or curiosity-driven panel and the result is positive, the practical step is simply to be aware. Know the symptoms of inflammatory back pain: onset before age 45, gradual development over weeks rather than sudden, improvement with exercise, worsening with inactivity, and nighttime pain that wakes you up. Know the signs of uveitis. If those things ever show up, mention your HLA-B27 status to your doctor, because it could shave months or even years off the time to diagnosis. Delayed diagnosis remains one of the biggest real-world problems in ankylosing spondylitis, with some patients waiting a decade or more between symptom onset and a correct diagnosis.
HLA-B27 Subtypes and Why They Matter
HLA-B27 is not a single molecule. There are over 160 recognized subtypes, designated B*2701, B*2702, and so on. Most of the disease risk appears concentrated in a few subtypes, particularly B*2705, which is the most common worldwide. Intriguingly, at least one subtype, B*2709, appears not to be associated with ankylosing spondylitis at all despite being structurally very similar to the disease-associated versions.1Elsevier / PubMed Central. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity
Standard clinical HLA-B27 tests do not distinguish between subtypes. They report you as positive or negative for the broader HLA-B27 family. This means a small number of people who test positive carry subtypes that likely pose little or no risk. Subtype-level testing exists in research settings but has not made its way into routine clinical care. For now, if you test positive, the assumption is that you carry a disease-associated subtype unless there is specific reason to investigate further. This is a reasonable assumption because the disease-associated subtypes vastly outnumber the rare non-associated ones in most populations.